株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

慢性創傷 - 洞察、疫学、市場予測 2028年

Chronic Wounds Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 915406
出版日 ページ情報 英文 260 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
慢性創傷 - 洞察、疫学、市場予測 2028年 Chronic Wounds Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年11月01日 ページ情報: 英文 260 Pages
概要

主要8カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本、中国)における慢性創傷の2017年の罹患数は2,662万1,142人、同年の市場規模は67億7,676万米ドルと推計されています。

当レポートでは、主要8カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本、中国)における慢性創傷市場を調査し、疾病の概要や疫学的予測、種類・国別の罹患数の推移と予測を詳細にまとめています。

目次

第1章 重要洞察

第2章 慢性創傷市場の概要

  • 慢性創傷の市場シェア(実績値)
  • 慢性創傷の市場シェア(予測値)

第3章 疾病背景と概要:慢性創傷

  • イントロダクション
  • 種類
  • 原因とリスク要因
  • 兆候と症状
  • 病態生理
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要8カ国の慢性創傷の総罹患数
  • 主要8カ国の慢性創傷の罹患数:種類別

第5章 米国の慢性創傷の疫学

  • 仮定と理論的根拠
  • 慢性創傷の罹患数
  • 慢性創傷の罹患数:種類別

第6章 EU5カ国の慢性創傷の疫学

  • 仮定と理論的根拠
  • ドイツ
    • 仮定と理論的根拠
    • 慢性創傷の罹患数
    • 慢性創傷の罹患数:種類別
  • フランス
  • イタリア
  • スペイン
  • 英国

第7章 日本の慢性創傷の疫学

  • 仮定と理論的根拠
  • 慢性創傷の罹患数
  • 慢性創傷の罹患数:種類別

第8章 中国の慢性創傷の疫学

  • 仮定と理論的根拠
  • 慢性創傷の罹患数
  • 慢性創傷の罹患数:種類別

第9章 治療アルゴリズムと現行治療

  • 糖尿病性足潰瘍
  • 静脈性足潰瘍
  • 褥瘡
  • 慢性創傷の治療

第10章 慢性創傷の治療ガイドライン

  • 米国
  • 欧州
  • 日本

第11章 アンメットニーズ

第12章 上市済み治療薬

  • REGRANEX(Becaplermin):Smith & Nephew
    • 製品説明
    • 規制のマイルストーン
    • 臨床開発
    • 安全性と有効性
    • 制限事項
    • 製品プロファイル
  • Fiblast (trafermin): 科研製薬

第13章 その他の治療法

  • 陰圧創傷療法(NPWT)
    • 概要
    • 長所と短所
    • 承認済み製品
  • 高圧酸素療法(HBOT)
  • 成長因子
  • 無細胞マトリックス組織
  • 創傷包帯

第14章 新薬

  • キークロスコンペティション
  • VM202:ViroMed BioPharma(Helixmith)
    • 製品説明
    • 臨床開発
    • 製品プロファイル
  • Galnobax (Esmolol Hydrochloride):Novalead Pharma
  • ALLO-ASC-DFU:Anterogen
  • WH-1 Ointment (ON101):Oneness Biotech
  • BAY1193397:Bayer
  • TTAX01:Tissue Tech/Amniox Medical
  • CSTC1:Charsire Biotechnology
  • ENERGI-F703:Energenesis Biomedical
  • EscharEx:MediWound
  • Absolve:Lynch Biologics
  • Taigexyn (Nemonoxacin):TaiGen Biotechnology
  • VPX638:Vapogenix
  • S42909:ILKOS THERAPEUTIC
  • Erythropoietin Hydrogel Formulation(RMD-G1):Remedor Biomed
  • ABCB5-positive Stem Cells:RHEACELL GmbH & Co. KG.

第15章 主要8カ国の慢性創傷市場の分析

  • 主な調査結果
  • 主要8カ国の市場規模
  • 主要8カ国の市場規模:治療薬別

第16章 米国市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第17章 欧州5カ国市場の見通し

  • ドイツの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模

第18章 日本市場の見通し

  • 日本の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第19章 中国市場の見通し

  • 中国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第20章 市場の成長要因

第21章 市場の障壁

第22章 付録

  • 調査手法

第23章 DelveInsightのサービス内容

第24章 免責事項

図表

List of Tables

  • Table 1 SYSTEMIC AND LOCAL FACTORS CONTRIBUTING TO CHRONIC WOUNDS
  • Table 2 PRESSURE ULCER GRADING SYSTEM, NPUAP, EPUAP AND PPPIA
  • Table 3 TYPES OF CHRONIC WOUNDS AND THEIR PATHOLOGY
  • Table 4 EXTENDED DIFFERENTIAL DIAGNOSIS FOR CHRONIC WOUNDS
  • Table 5 TOTAL INCIDENT POPULATION OF CHRONIC WOUND IN THE G8 COUNTRIES (2017-2028)
  • Table 6 TYPE-SPECIFIC DIAGNOSED INCIDNCE OF CHRONIC WOUNDS IN THE G8 COUNTRIES (2017-2028)
  • Table 7 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN THE US (2017-2028)
  • Table 8 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN THE UNITED STATES (2017-2028)
  • Table 9 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN GERMANY (2017-2028)
  • Table 10 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN GERMANY (2017-2028)
  • Table 11 TOTAL PREVALENT POPULATION OF CHRONIC WOUNDS IN FRANCE (2017-2028)
  • Table 12 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUND IN FRANCE (2017-2028)
  • Table 13 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN ITALY (2017-2028)
  • Table 14 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN ITALY (2017-2028)
  • Table 15 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN SPAIN (2017-2028)
  • Table 16 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN SPAIN (2017-2028)
  • Table 17 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN THE UNITED KINGDOM (2017-2028)
  • Table 18 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN THE UNITED KINGDOM (2017-2028)
  • Table 19 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN JAPAN (2017-2028)
  • Table 20 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN JAPAN (2017-2028)
  • Table 21 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN CHINA (2017-2028)
  • Table 22 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN CHINA (2017-2028)
  • Table 23 TIME PRINCIPLES OF WOUND BED PREPARATION
  • Table 24 TYPES OF CHRONIC WOUNDS AND THEIR SPECIFIC THERAPY
  • Table 25 RECOMMENDATIONS ON USE OF ANTIMICROBIAL DRESSINGS IN WOUNDS
  • Table 26 WOUND CARE TECHNOLOGIES
  • Table 27 CLINICAL PRACTICE GUIDELINE FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC FOOT INFECTIONS (DFI)
  • Table 28 GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF FOOT INFECTIONS IN PERSONS WITH DIABETES
  • Table 29 GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF FOOT INFECTIONS IN PERSONS WITH DIABETES
  • Table 30 GUIDELINES FOR THE DIAGNOSIS AND TREATMENT FOR PRESSURE ULCERS: JAPANESE DERMATOLOGICAL ASSOCIATION (JDA)
  • Table 31 FIBLAST, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 32 APPROVED ADVANTAGES AND DISADVANTAGES OF NPWT
  • Table 33 EXAMPLES OF APPROVED HYPERBARIC OXYGEN THERAPY (HBOT) PRODUCTS
  • Table 34 PARTIAL LIST OF GROWTH FACTORS USED TO ACCELERATE THE REPAIR OF CHRONIC WOUNDS IN HUMANS
  • Table 35 APPROVED PRODUCTS OF GROWTH FACTORS
  • Table 36 ADVANTAGES AND DISADVANTAGES OF CELLULAR MATRIX DRESSINGS
  • Table 37 EXAMPLES OF APPROVED MATRIX TISSUES PRODUCTS
  • Table 38 ADVANTAGES AND DISADVANTAGES OF WOUND DRESSING
  • Table 39 FEW EXAMPLES OF APPROVED WOUND DRESSING FOR WOUND CARE
  • Table 40 EMERGING DRUGS ANALYSIS
  • Table 41 EMERGING DRUGS ANALYSIS (CONTINUED)
  • Table 42 EMERGING DRUGS ANALYSIS (CONTINUED)
  • Table 43 EMERGING DRUGS ANALYSIS (CONTINUED)
  • Table 44 VM202, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 45 GALNOBAX, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 46 ALLO-ASC-DFU, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 47 WH-1 OINTMENT, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 48 BAY1193397, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 49 TTAX01, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 50 CSTC1, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 51 ENERGI-F703, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 52 ESCHAREX, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 53 ABSOLVE, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 54 TG-873870 (NEMONOXACIN) CLINICAL TRIAL DESCRIPTION, 2019
  • Table 55 VPX638, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 56 S42909, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 57 ERYTHROPOIETIN HYDROGEL FORMULATION, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 58 ABCB5-POSITIVE STEM CELLS, CLINICAL TRIAL DESCRIPTION, 2019
  • Table 59 MARKET SIZE OF CHRONIC WOUNDS IN G8 COUNTRIES IN USD MILLION (2017-2028)
  • Table 60 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE G8 COUNTRIES, IN USD MILLION (2017-2028)
  • Table 61 EMERGING THERAPIES TO BE LAUNCHED IN THE UNITED STATES
  • Table 62 THE US MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 63 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017-2028)
  • Table 64 EMERGING THERAPIES TO BE LAUNCHED IN THE EU-5
  • Table 65 GERMANY MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 66 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN GERMANY, IN USD MILLION (2017-2028)
  • Table 67 FRANCE MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 68 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN FRANCE, IN USD MILLION (2017-2028)
  • Table 69 ITALY MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 70 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN ITALY, IN USD MILLION (2017-2028)
  • Table 71 SPAIN MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 72 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN SPAIN, IN USD MILLION (2017-2028)
  • Table 73 THE UK MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 74 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE UK, IN USD MILLION (2017-2028)
  • Table 75 JAPAN MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 76 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN JAPAN IN USD MILLION (2017-2028)
  • Table 77 JAPAN MARKET SIZE OF CHRONIC WOUNDS IN USD MILLION (2017-2028)
  • Table 78 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN CHINA, IN USD MILLION (2017-2028)

List of Figures

  • Figure 1 FLOW DIAGRAM OF CHRONIC WOUND MANAGEMENT.
  • Figure 2 TYPES OF CHRONIC WOUNDS
  • Figure 3 CAUSE HIERARCHY OF PRESSURE ULCERS (PU) AND DIABETIC FOOT ULCERS (DFU)
  • Figure 4 ARTERIAL INSUFFICIENCY ULCER LOCATED AT WEIGHT BEARING SURFACE.
  • Figure 5 VENOUS ULCERS WITH GRANULATED WOUND BED AND SURROUNDING DRY, SCALY, ECZEMATOUS, AND HYPERPIGMENTED SKIN.
  • Figure 6 DIABETIC FOOT ULCER AT FIRST METATARSAL HEAD OF THE FOOT
  • Figure 7 MOLECULAR AND CELLULAR DEFICIENCIES IN CHRONIC WOUNDS (RED CIRCLES) AND FACTORS REQUIRED TO OVERCOME THEM (GREEN RECTANGLES).
  • Figure 8 PATHOPHYSIOLOGY OF CHRONIC WOUNDS
  • Figure 9 THE ROLE OF INFLAMMATION IN THE PATHOPHYSIOLOGY OF COMMON CHRONIC WOUNDS.
  • Figure 10 DIAGNOSING CHRONIC WOUNDS: THE ABCDE RULE
  • Figure 11 TOTAL INCIDENT POPULATION OF CHRONIC WOUND IN THE G8 COUNTRIES (2017-2028)
  • Figure 12 TYPE-SPECIFIC INCIDNCE OF CHRONIC WOUNDS IN THE G8 COUNTRIES (2017-2028)
  • Figure 13 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN THE US (2017-2028)
  • Figure 14 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN THE UNITED STATES (2017-2028)
  • Figure 15 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN GERMANY (2017-2028)
  • Figure 16 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN GERMANY (2017-2028)
  • Figure 17 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN FRANCE (2017-2028)
  • Figure 18 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUND IN FRANCE (2017-2028)
  • Figure 19 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN ITALY (2017-2028)
  • Figure 20 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN ITALY (2017-2028)
  • Figure 21 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN SPAIN (2017-2028)
  • Figure 22 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN SPAIN (2017-2028)
  • Figure 23 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN THE UNITED KINGDOM (2017-2028)
  • Figure 24 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN THE UNITED KINGDOM (2017-2028)
  • Figure 25 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN JAPAN (2017-2028)
  • Figure 26 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN JAPAN (2017-2028)
  • Figure 27 TOTAL INCIDENT POPULATION OF CHRONIC WOUNDS IN CHINA (2017-2028)
  • Figure 28 TYPE-SPECIFIC INCIDENCE OF CHRONIC WOUNDS IN CHINA (2017-2028)
  • Figure 29 SIMPLIFIED ALGORITHM FOR DIABETIC FOOT ULCER (DFU) TREATMENT.
  • Figure 30 SIMPLIFIED ALGORITHM FOR VENOUS LEG ULCER (VLU) TREATMENT. ABI, ANKLE-BRACHIAL INDICES.
  • Figure 31 ALGORITHM FOR MANAGEMENT OF PRESSURE ULCER.
  • Figure 32 UNMET NEEDS
  • Figure 33 MECHANISMS OF ACTION INVOLVED IN NEGATIVE PRESSURE WOUND THERAPY
  • Figure 34 THERAPEUTIC MECHANISMS OF HBO2 RELATED TO ELEVATIONS OF TISSUE OXYGEN TENSIONS
  • Figure 35 MARKET SIZE OF CHRONIC WOUNDS IN THE G8 COUNTRIES IN USD MILLION (2017-2028)
  • Figure 36 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE G8 COUNTRIES, IN USD MILLION (2017-2028)
  • Figure 37 MARKET SIZE OF CHRONIC WOUNDS IN THE US, USD MILLIONS (2017-2028)
  • Figure 38 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017-2028)
  • Figure 39 MARKET SIZE OF CHRONIC WOUNDS IN GERMANY, USD MILLIONS (2017-2028)
  • Figure 40 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN GERMANY, IN USD MILLION (2017-2028)
  • Figure 41 MARKET SIZE OF CHRONIC WOUNDS IN FRANCE, USD MILLIONS (2017-2028)
  • Figure 42 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN FRANCE, IN USD MILLION (2017-2028)
  • Figure 43 MARKET SIZE OF CHRONIC WOUNDS IN ITALY, USD MILLIONS (2017-2028)
  • Figure 44 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN ITALY IN USD MILLION (2017-2028)
  • Figure 45 MARKET SIZE OF CHRONIC WOUNDS IN SPAIN, USD MILLIONS (2017-2028)
  • Figure 46 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN SPAIN IN USD MILLION (2017-2028)
  • Figure 47 MARKET SIZE OF CHRONIC WOUNDS IN THE UK, USD MILLIONS (2017-2028)
  • Figure 48 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN THE UNITED KINGDOM IN USD MILLION (2017-2028)
  • Figure 49 MARKET SIZE OF CHRONIC WOUNDS IN JAPAN, USD MILLIONS (2017-2028)
  • Figure 50 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN JAPAN IN USD MILLION (2017-2028)
  • Figure 51 MARKET SIZE OF CHRONIC WOUNDS IN CHINA, USD MILLIONS (2017-2028)
  • Figure 52 MARKET SIZE OF CHRONIC WOUNDS BY THERAPIES IN CHINA IN USD MILLION (2017-2028)
  • Figure 53 MARKET DRIVERS
  • Figure 54 MARKET BARRIERS
目次
Product Code: DIMI0642

DelveInsight's Chronic Wounds - Market Insights, Epidemiology, and Market Forecast-2028 (G8) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Chronic Wounds in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of chronic wounds from 2017 to 2028 segmented by the eight major markets.

The current treatment market for chronic wounds is predominated by medical devices, hydrogels, and off-label antibacterial drugs. In addition to this, preventative and treatment measures of chronic wounds include disease-specific approaches, like the use of moisture-retentive dressings, bioengineered dressings, adjunctive topical therapies to promote healing, debridement, negative pressure therapy (NPWT), and Hyperbaric oxygen therapy (HBOT).

Moreover, emerging therapies, like ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound), which is in the late-stage pipeline, are expected to launch during the forecast period [2019-2028]. The increasing incidence, inefficacy of present therapies, awareness of the disease, and promising emerging pipeline therapies shall propel the market size forward in the coming years.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2017-2028

Chronic Wounds - Disease Understanding and Treatment Algorithm

Chronic wounds are wounds in which the normal process of healing has been disrupted at one or more points in the phases of hemostasis, inflammation, proliferation, and remodeling. In this wound type, there is usually an underlying pathology, which produces a delay in the healing process. Common skin injuries and delays or poor healing of wounds do not always turn into chronic wounds. Therefore, diagnosis depends on the patient history, which involves various risk factors, like diabetes, a weak immune system, or circulation problems. The wound can be assessed by its depth and size, color, smell, and the severity of pain and itching.

Chronic wounds are mainly caused by conditions that slow or stop the healing process, such as poor blood supply or low oxygen, an infection, weak immune system, swelling in the tissues around the wound. These are mainly classified as vascular ulcers (e.g., venous and arterial ulcers), diabetic ulcers, and pressure ulcers. Some common features shared by each of these wounds include prolonged or excessive inflammation, persistent infections, the formation of drug-resistant microbial biofilms, and the inability of dermal and/or epidermal cells to respond to reparative stimuli. In aggregate, these pathophysiologic phenomena result in the failure of these wounds to heal.

DelveInsight's chronic wounds market report gives a thorough understanding of the chronic wounds by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for chronic wounds in the US, Europe, Japan, and China.

Chronic Wounds - Epidemiology

The chronic wounds epidemiology division provides insights about historical and current patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Chronic Wound in the G8 Countries, and Type-Specific Incidence of Chronic Wounds in the G8] scenario of chronic wounds in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom), Japan, and China from 2017-2028.

As per DelveInsight's analysis, the total Incident Population of Chronic Wounds in the G8 countries was found to be 26,621,142 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in China followed by the United States and among the European-5 countries, Germany had the highest incident population of chronic wounds followed by France and Italy.

On the other hand, Spain had the lowest incident population of chronic wounds. Another estimate of Delveinsight's analysis based on the type of Chronic Wounds showed that Diabetic Foot Ulcers accounted for the highest patient pool in the G8 countries, while Pressure Ulcer and Venous Ulcer cases account for nearly one-fourth, each, of the total chronic wounds population.

Chronic Wounds - Drug Chapters

This segment of the chronic wounds report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment and market of chronic wounds are dependent on medical devices, hydrogels, and off-label antibacterial drugs as well as emerging therapies. In emerging therapies following drugs are there ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), EscharEx (MediWound), BAY1193397 (Bayer), CSTC1 (Charsire Biotechnology), ENERGI-F703 (Energenesis Biomedical), and others.

VM202 (ViroMed BioPharma) is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits. Currently, VM202 is in Phase III clinical trial to assess the safety and efficacy of VM202 to treat chronic nonhealing foot ulcers in diabetic patients with the concomitant peripheral arterial disease (PAD).

On the other hand, Galnobax, by Novalead Pharma, is a topical gel of Esmolol hydrochloride for the treatment of hard to heal diabetic foot ulcers. It is a repurposed generic drug molecule, which has completed global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both, safety and efficacy.

Another novel approach for managing these nonhealing wounds is stem-cell therapies. Mesenchymal stem cells (MSCs) may hold great promise for treating diabetic wounds because they have advantages as allogeneic and autologous cells. Adipose-derived stem cells (ASCs) have been demonstrated to be one of the main sources of MSCs. Anterogen is coming up with ALLO-ASC-DFU, which is allogeneic mesenchymal stem cells. This product is in late-stage of development and is expected to launch during the forecast period 2019-2028.

Additionally, Oneness Biotech also coming up with its new botanical drug ointment, ON101. Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation. According to the interim results of its ongoing phase III clinical trial, the clinical efficacy of ON101 is better than the current drug Regranex, and it will be the first natural source of therapeutic drugs for DFU with the greatest value in the market.

Another company, Tissue Tech, which is developing a product TTAX01 for the management of venous leg ulcers and nonhealing wounds. This therapy is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, cesarian section, full-term births after determination of donor eligibility and placenta suitability.

Chronic Wounds - Market Outlook

The chronic wounds market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to Delveinsight's the market size of chronic wounds was USD 6,776.76 million in 2017. The current therapeutic market of chronic wounds is the G8 countries is dependent on medical devices, hydrogels, off-label antibacterial drugs, and dressings and the expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of chronic wounds and awareness of the disease.

It was also attributed that the market size of analgesics and neuroleptics was found to be higher among the patients with Diabetic Foot Ulcers, contributing 47.46% of the Diabetic Foot Ulcer market share. This was followed by the contribution of anti-infective therapies, while for those suffering from venous ulcers, anti-infective therapies accommodate the highest share. In all G8 countries, the United States accounted for the highest market size for chronic wounds of the total G8 market in comparison to EU5, Japan and China.

Expected launch of ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound) for the treatment of chronic wounds, during the forecast period [2019-2028] will create a positive impact on chronic wounds treatment market.

Chronic Wounds - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allowing the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of chronic wounds market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for chronic wounds.

To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of chronic wounds during our forecast period, including ON101 (Oneness Biotech), VM202 (ViroMed BioPharma), Galnobax (Novalead Pharma), ALLO-ASC-DFU (Anterogen), TTAX01 (Tissue Tech/Amniox Medical), and EscharEx (MediWound).

Chronic Wounds Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Wounds Report Key Strengths

  • 10 Years Forecast
  • G8 Countries Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Chronic Wounds Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic Wounds market
  • Organize sales and marketing efforts by identifying the best opportunities for chronic wounds market
  • To understand the future market competition in the chronic wounds market.

Table of Contents

1. Key Insights

2. Chronic Wounds: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Chronic Wounds in 2017
  • 2.2. Total Market Share (%) Distribution of Chronic Wounds in 2028

3. Chronic Wounds: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types of Chronic Wounds
  • 3.3. Causes and Risk Factors of Chronic Wound
    • 3.3.1. Causes of Chronic Wounds According to Types
  • 3.4. Signs and Symptoms of Chronic Wounds
  • 3.5. Pathophysiology of Chronic Wounds
    • 3.5.1. The Role of Inflammation in the Pathophysiology of Common Chronic Wounds
  • 3.6. Diagnosis of Chronic Wounds

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Incident Population of Chronic Wounds in the G8 Countries
  • 4.3. Type-Specific Incidence of Chronic Wounds in the G8 Countries

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Incident Population of Chronic Wounds in the United States
  • 5.3. Type-Specific Incidence of Chronic Wounds in the United States

6. EU5 Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Germany Epidemiology
    • 6.2.1. Total Incident Population of Chronic Wounds in Germany
    • 6.2.2. Type-Specific Incident Population of Chronic Wounds in Germany
  • 6.3. France Epidemiology
    • 6.3.1. Total Incident Population of Chronic Wounds in France
    • 6.3.2. Type-Specific Incidence of Chronic wound in France
  • 6.4. Italy Epidemiology
    • 6.4.1. Total Incident Population of Chronic wounds in Italy
    • 6.4.2. Type-Specific Incidence of Chronic Wounds in Italy
  • 6.5. Spain Epidemiology
    • 6.5.1. Total Incident Population of Chronic Wounds in Spain
    • 6.5.2. Type-Specific Incidence of Chronic Wounds in Spain
  • 6.6. United Kingdom Epidemiology
    • 6.6.1. Total Incident Population of Chronic Wounds in the United Kingdom
    • 6.6.2. Type-Specific Incidence of Chronic Wounds in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Incident Population of Chronic Wounds in Japan
  • 7.3. Type-Specific Incidence of Chronic Wounds in Japan

8. China Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Total Incident Population of Chronic Wounds in China
  • 8.3. Type-Specific Incidence of Chronic Wounds in China

9. Treatment Algorithm, Current Treatment, and Medical Practices

  • 9.1. Treatment Algorithm for Diabetic Foot Ulcer
  • 9.2. Treatment Algorithm for Venous Leg Ulcer
  • 9.3. Treatment Algorithm for Pressure Ulcer
  • 9.4. Treatment of Chronic Wounds

10. Guidelines for Chronic Wound Care

  • 10.1. United States
    • 10.1.1. Chronic Wound Care Guidelines: The Wound Healing Society
    • 10.1.2. Infectious Diseases Society of America (IDSA): Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections
  • 10.2. Europe
    • 10.2.1. The International Working Group on the Diabetic Foot (IWGDF): Guidelines on the diagnosis and management of foot infections in persons with diabetes
    • 10.2.2. National Institute of Health and Care Excellence (NICE): Guidelines Prevention and Management of Pressure Ulcers
  • 10.3. Japan
    • 10.3.1. Guidelines for the Diagnosis and Treatment for Pressure Ulcers: Japanese Dermatological Association (JDA)

11. Unmet Needs

12. Marketed Products

  • 12.1. REGRANEX (Becaplermin): Smith & Nephew
    • 12.1.1. Product Description
    • 12.1.2. Regulatory Milestones
    • 12.1.3. Clinical Development
    • 12.1.4. Safety and Efficacy
    • 12.1.5. Limitations
    • 12.1.6. Product Profile
  • 12.2. Fiblast (trafermin): Kaken Pharmaceutical
    • 12.2.1. Product Description
    • 12.2.2. Regulatory Milestones
    • 12.2.3. Clinical Development
    • 12.2.4. Product Profile

13. Other Marketed Products

  • 13.1. Negative Pressure Wound Therapy (NPWT)
    • 13.1.1. Description
    • 13.1.2. Advantages and Disadvantages
    • 13.1.3. Approved Products
  • 13.2. Hyperbaric Oxygen Therapy (HBOT)
    • 13.2.1. Description
    • 13.2.2. Approved Products
  • 13.3. Growth Factors
    • 13.3.1. Description
    • 13.3.2. Approved Products
  • 13.4. Acellular Matrix Tissues
    • 13.4.1. Description
    • 13.4.2. Advantages and Disadvantages
    • 13.4.3. Approved Products
  • 13.5. Wound Dressings
    • 13.5.1. Advantages and Disadvantages
    • 13.5.2. Approved Products

14. Emerging Therapies

  • 14.1. Key Cross Competition
  • 14.2. VM202: ViroMed BioPharma (Helixmith)
    • 14.2.1. Product Description
    • 14.2.2. Clinical Development
    • 14.2.3. Product Profile
  • 14.3. Galnobax (Esmolol Hydrochloride): Novalead Pharma
    • 14.3.1. Product Description
    • 14.3.2. Other Developmental Activities
    • 14.3.3. Clinical Development
    • 14.3.4. Safety and Efficacy
    • 14.3.5. Product Profile
  • 14.4. ALLO-ASC-DFU: Anterogen
    • 14.4.1. Product Description
    • 14.4.2. Other Developmental Activities
    • 14.4.3. Clinical Development
    • 14.4.4. Safety and Efficacy
    • 14.4.5. Product Profile
  • 14.5. WH-1 Ointment (ON101): Oneness Biotech
    • 14.5.1. Product Description
    • 14.5.2. Other Developmental Activities
    • 14.5.3. Clinical Development
    • 14.5.4. Product Profile
  • 14.6. BAY1193397: Bayer
    • 14.6.1. Product Description
    • 14.6.2. Clinical Development
    • 14.6.3. Product Profile
  • 14.7. TTAX01: Tissue Tech/Amniox Medical
    • 14.7.1. Product Description
    • 14.7.2. Other Development Activities
    • 14.7.3. Clinical Development
    • 14.7.4. Product Profile
  • 14.8. CSTC1: Charsire Biotechnology
    • 14.8.1. Product Description
    • 14.8.2. Other Developmental Activities
    • 14.8.3. Clinical Development
    • 14.8.4. Product Profile
  • 14.9. ENERGI-F703: Energenesis Biomedical
    • 14.9.1. Product Description
    • 14.9.2. Other Developmental Activities
    • 14.9.3. Clinical Development
    • 14.9.4. Product Profile
  • 14.10. EscharEx: MediWound
    • 14.10.1. Product Description
    • 14.10.2. Other Developmental Activities
    • 14.10.3. Clinical Development
    • 14.10.4. Safety and Efficacy
    • 14.10.5. Product Profile
  • 14.11. Absolve: Lynch Biologics
    • 14.11.1. Product Description
    • 14.11.2. Clinical Development
    • 14.11.3. Product Profile
  • 14.12. Taigexyn (Nemonoxacin): TaiGen Biotechnology
    • 14.12.1. Product Description
    • 14.12.2. Other Developmental Activities
    • 14.12.3. Clinical Development
    • 14.12.4. Safety and Efficacy
    • 14.12.5. Product Profile
  • 14.13. VPX638: Vapogenix
    • 14.13.1. Product Description
    • 14.13.2. Other Developmental Activities
    • 14.13.3. Clinical Development
    • 14.13.4. Product Profile
  • 14.14. S42909: ILKOS THERAPEUTIC
    • 14.14.1. Product Description
    • 14.14.2. Other Development Activities
    • 14.14.3. Clinical Development
    • 14.14.4. Product Profile
  • 14.15. Erythropoietin Hydrogel Formulation(RMD-G1): Remedor Biomed
    • 14.15.1. Product Description
    • 14.15.2. Other Development Activities
    • 14.15.3. Clinical Development
    • 14.15.4. Product Profile
  • 14.16. ABCB5-positive Stem Cells: RHEACELL GmbH & Co. KG.
    • 14.16.1. Product Description
    • 14.16.2. Other Developmental Activities
    • 14.16.3. Clinical Development
    • 14.16.4. Product Profile

15. Chronic Wounds: G8 Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Size of Chronic Wounds in G8 Countries
  • 15.3. Market Size of Chronic Wounds by Therapies in the G8

16. United States: Market Outlook

  • 16.1. United States Market Size
    • 16.1.1. Total Market size of Chronic Wounds in the United States
    • 16.1.2. Market Size of Chronic Wounds by Therapies in the US

17. EU-5 countries: Market Outlook

  • 17.1. Germany Market Size
    • 17.1.1. Total Market size of Chronic Wounds in Germany
    • 17.1.2. Market Size of Chronic Wounds by therapies in Germany
  • 17.2. France Market Size
    • 17.2.1. Total Market size of Chronic Wounds in France
    • 17.2.2. Market Size of Chronic Wounds by therapies in France
  • 17.3. Italy Market Size
    • 17.3.1. Total Market size of Retinitis Pigmentosa in Italy
    • 17.3.2. Market Size of Chronic Wounds by therapies in Italy
  • 17.4. Spain Market Size
    • 17.4.1. Total Market size of Chronic Wounds in Spain
    • 17.4.2. Market Size of Chronic Wounds by therapies in Spain
  • 17.5. United Kingdom Market Size
    • 17.5.1. Total Market size of Chronic Wounds in the United Kingdom
    • 17.5.2. Market Size of Chronic Wounds by therapies in the UK

18. Japan Market Outlook

  • 18.1. Japan Market Size
    • 18.1.1. Total Market size of Chronic Wounds in Japan
    • 18.1.2. Market Size of Chronic Wounds by therapies in Japan

19. China Market Outlook

  • 19.1. China Market Size
    • 19.1.1. Total Market size of Chronic Wounds in China
    • 19.1.2. Market Size of Chronic Wounds by therapies in China

20. Market Drivers

21. Market Barriers

22. Appendix

  • 22.1. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

Back to Top